Cosmetic cross-reference Noindex: medium evidence

Chymotrypsin

CAS 9004-07-3

Chymotrypsin (CAS 9004-07-3) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE DrugCentral 055904D152D6

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Chymotrypsin
CAS Number
9004-07-3
UNII
BVS505O332
ChEMBL ID
CHEMBL1201465
DrugCentral Struct ID
5040
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
chymotrypsin 2530 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Chymotrypsin used for in pharmaceutical contexts?

Chymotrypsin (CAS 9004-07-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Chymotrypsin?

No adverse-event association or SIDER side-effect rows are rendered for Chymotrypsin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Chymotrypsin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Chymotrypsin with EU status "restricted".

What clinical phase is Chymotrypsin in?

No phase 1-4 clinical development badge is rendered for Chymotrypsin because the matched compound identifier rows do not contain a max-phase value.